ResearchSafe

GLP-1 patent cliffs and the generic wave coming for semaglutide

Posted by liam_sleepnerd in Research & News - 1 points, 4 comments.

https://www.chemistryworld.com/news/indias-generic-glp-1-drugs-are-mostly-booming/4023975.article

This piece in C&EN lays out what's fixin' to happen as semaglutide and the rest of the GLP-1 class start losing patent protection, with Indian, Chinese, and European generics firms already lining up. The interesting bit is how quickly the pricing pressure could reshape access, since branded supply has been the bottleneck for most folks I know.

My honest take, this is the real story, not the next me-too GLP-1. I've watched patients and friends sit on waiting lists or ration doses because of sticker shock, so cheaper generics would change a lot of behavior at the clinic level. The catch is quality control, because the FDA crackdown stories from earlier this year showed how messy the supply chain gets when demand outruns oversight.

What worries me is the transition period, when compounded versions get squeezed out at the same time generics are still ramping up. Are y'all expecting a coverage gap, or do you think the big manufacturers will absorb the shock?

Comments

  • ethan_hrv: The patent timing is the real story, agree. Once the indian and chinese api manufacturers get their lines validated the price floor drops fast, that's just how these markets work. The gap is what i'd watch closely. Compounded pharmacies filled a real void for people paying out of pocket, and once those get shut down but generic ozempic isn't on shelves yet, that's months of awkward access. I remember a buddy stretching his dose to twice a week because he couldn't refill, not a great plan. The
  • liam_sleepnerd: Yeah, that gap is exactly the part that gives me pause, your buddy stretching doses is a textbook example of what I'm worried about. People are smart about it, but they're making rationing calls with a peptide that has a half life that doesn't really reward that kind of spacing. On the FDA piece, tbh that's where I land too, and your phrasing of "cheaper doesn't mean equivalent" is the cleanest way I've seen it put. The earlier 503A/503B drama already showed how fast bad batches slip through wh
  • miles_codes: Yeah the gap is the ugly part. Compounded sema wasn't perfect but it kept a lot of people moving when branded supply dried up. If those scripts get cut off before generics actually land on shelves, you're gonna have a rough few months of people stretching doses or just going without. The API quality question matters too, since not every overseas manufacturer is gonna hit the same purity bar and the FDA doesn't have the bandwidth to inspect them all.
  • liam_sleepnerd: Totally agree on the gap, that's the part I keep coming back to. Compounded sema wasn't elegant but it was a pressure release valve, and I know a few people who titrated up from a 503B because that's what was actually available, not because it was their first choice. On API quality, that's what scares me most tbh. The Indian and Chinese firms can make it cheap, but I've seen enough chromatography data from gray market stuff to know the variance is real, not theoretical. Curious what y'all thin

Community discussion - research and educational context only. Not medical advice.